AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05898347 — intervention group
Intervention type: OTHER
Intervention: Active surveillance
Description: Skin lesions clinically compatible with nevoid basal cell carcinomas are documented with measurements, clinical description, clinical photos and dermatoscopy photos every eight months for two years. Three representative skin lesions are selected at the first visit to be removed by skin biopsy at the end of the observation period (two years) for histopathological analyses.~If a nevoid basal cell carcinoma shows a certain increases in size (according to pre-specified criteria of the study protocol), ulcerates, gets unevenly demarcated or give functional complaints during the observation period, the skin lesion will be excised.
Study NCT05665504 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: DetermaRX
Description: A lung tissue biomarker to risk stratify patients immediately after curative lung cancer resections into groups with low risk versus intermediate-high risk for recurrence of cancer. Intermediate-high risk patients will be advised to undergo adjuvant chemotherapy with the expectation of decreasing their chance of recurrence. The effectiveness and toxicity of the adjuvant chemotherapy itself is considered not part of the study-just the decision to recommend adjuvant chemotherapy is the study intervention. Investigators will then evaluate the long-term survival results of low-risk patients (no adjuvant treatment) and intermediate-high risk patients receiving adjuvant treatment versus intermediate-high risk patients who decline adjuvant therapy.
Study NCT06168539 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Emboless
Description: Emboless has the US patent number 8894749 is compared to standard dialysis See also reference Jonsson et al 2023 referred to in the main text.
Study NCT06168539 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard
Description: Standard dialysis set is used as comparative
Study NCT05336214 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual CGM initiation service
Description: Primary care practices will refer patients to an external virtual initiation service staffed by clinical pharmacists, diabetes care and education specialists, and physicians. The initiation service will communicate with eligible patients (referred to the virtual initiation service by their provider) to review device options and provide patient education and support on device use for up to 12 months to help initiate use of the device. The initiation service will communicate with a patient's provider about treatment and follow up, but will not make treatment recommendations directly to patients.
Study NCT05336214 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online educational module on CGM
Description: Primary care practices will complete online educational modules, the American Academy of Family Physicians Transformation in Practice Series on CGM. This series includes education on diabetes; glucose monitoring; evidence behind CGM; CGM implementation tools, strategies, and workflows; billing, reimbursement, and insurance authorization of CGM; and tools and strategies to use CGM for quality improvement in diabetes care.
Study NCT05336214 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Practice facilitation
Description: A practice facilitator will support primary care practices in training team members using the American Academy of Family Physicians Transformation in Practice Series on CGM and in implementation of strategies to support CGM use for patients with diabetes in primary care.
Study NCT06269705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZILRETTA
Description: IA injection of 32 mg ZILRETTA
Study NCT06269705 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TCA-IR
Description: IA injection of 40 mg TCA-IR
Study NCT06269705 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IA injection of placebo (normal saline)
Study NCT06465953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivosidenib
Description: Two 250 mg tablets, totaling 500 mg, administered orally once daily until disease relapse or progression, unacceptable toxicity, confirmed pregnancy, undergoing HSCT, death, withdrawal of consent, lost to follow-up, or Sponsor ending the study, whichever occurs first.
Study NCT06465953 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine 75mg/m\^2/day administered by subcutaneous (SC) or intravenous (IV) injection for 1 week (7 days) of each 4-week (28 day) treatment cycle until disease relapse or progression, unacceptable toxicity, confirmed pregnancy, undergoing HSCT, death, withdrawal of consent, lost to follow-up, or Sponsor ending the study, whichever occurs first.
Study NCT06239636 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UP421
Description: Intramuscular transplantation with the ATMP UP421 composed of genetically modified human pancreatic islet cells
Study NCT06549790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NMS-03597812
Description: Route of Administration: Oral
Study NCT06500793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF614 capsule
Description: PF614 capsules (25-100 mg)
Study NCT06500793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nafamostat Mesylate
Description: Nafamostat IR/ER solution/beads (total 1-10 mg)
Study NCT06258850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcifediol Oral Capsule
Description: One Hydroferol® soft capsule (0.266 mg) will be administered once weekly for the first 12 weeks and one capsule every two weeks for the next 12 weeks.
Study NCT06258850 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One soft capsule will be administered once weekly for the first 12 weeks and one capsule every two weeks for the next 12 weeks.
Study NCT06369558 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PLYOMETRIC TRAINING
Description: A 6 WEEK (3 TIMES A WEEK) CONSISTING OF JUMPING SINGLE LEG BRIDGE AND JUMPED SQUAT
Study NCT06369558 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PLYOMETRIC TRAINING
Description: A 6 WEEK (3 TIMES A WEEK) CONSISTING OF JUMPING SINGLE LEG BRIDGE AND JUMPED SQUAT
Study NCT06369558 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CLASSIC PHYSIOTHERAPY PROGRAM
Description: HOT PACKED ENTEFERANTIAL CURRENT THERAPY AND US THERAPY
Study NCT06249581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AUX-001 40mg once-daily
Description: AUX-001 (extended-release nicorandil) 40mg QD (once-daily)
Study NCT05540145 — intervention group
Intervention type: DRUG
Intervention: SOX plus Paclitaxel with or without antiangiogenesis followed by PD-1 antibody
Description: Drug: Paclitaxel(albumin-bound) 130mg/m2, ivgtt, D1, Q2w Drug: Oxaliplatin 70 mg/m2, ivgtt, D1, q2w Drug: S-1 40mg (body surface area \< 1.25m2), bid, D1-8, Q2w 50mg (body surface area >1.25m2, \<1.5 m2), bid, D1-8, Q2w 60mg (body surface area >1.5m2), bid, D1-8, Q2w Drug: Bevacizumab, 5mg/kg, ivgtt, D1, Q14d Drug: PD-1 antibody, 200mg, ivgtt, D1, Q21d Patients with Her-2 negative, MMR-proficient locally advanced esophagogastric junction or gastric adenocarcinoma will receive 6 cycles of neoadjuvant chemotherapy with or without antiangiogenesis. After comprehensive evaluations, patients who respond to chemotherapy will further receive 2 cycles of PD-1 antibody comibed with antiangiogenesis and chemotherapy as neoadjuvant therapy.~Drug: Pembrolizumab or sintilimab, 100\~200mg, ivgtt, D1, Q3w. Patients will make the final decision of PD -1 antibody according to their economic condition.
Study NCT06273761 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medication Management Service (MMS)
Description: Medication Management Service (MMS) is a service delivered by community pharmacists aiming at helping patients resolve their medication therapy problems (MTPs) by carrying out medication reconciliation, provision of education about their medication regimen, and also providing professional pharmacological advice to patients.
Study NCT06207474 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Video + Chatbot
Description: Participants will receive detailed information about the radiation therapy process, potential side effects, frequently asked questions, and aftercare instructions using a combination of educational videos and interactive chatbot sessions.
Study NCT06207474 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Video + Paper
Description: Participants will receive detailed information about the radiation therapy process, potential side effects, frequently asked questions, and aftercare instructions using a combination of educational videos and paper materials.
Study NCT06207474 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Paper + Chatbot
Description: Participants will receive detailed information about the radiation therapy process, potential side effects, frequently asked questions, and aftercare instructions using a combination of paper materials and interactive chatbot sessions.
Study NCT06207474 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Paper + Paper
Description: Participants will receive detailed information about the radiation therapy process, potential side effects, frequently asked questions, and aftercare instructions using paper materials.
Study NCT06209632 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mirror therapy
Description: 30 minutes of intervention, twice a week, and a total of 12 weeks
Study NCT06209632 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: contralaterally controlled functional electrical stimulation
Description: 30 minutes of intervention, twice a week, and a total of 12 weeks
Study NCT06209632 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: contralaterally controlled functional electrical stimulation
Description: 30 minutes of intervention, twice a week, and a total of 12 weeks
Study NCT06209632 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: conventional physiotherapy
Description: 50 minutes of intervention, twice a week, and a total of 12 weeks
Study NCT06209632 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: conventional physiotherapy
Description: 50 minutes of intervention, twice a week, and a total of 12 weeks
Study NCT06209632 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: conventional physiotherapy
Description: 50 minutes of intervention, twice a week, and a total of 12 weeks
Study NCT05334394 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mulligan Technique
Description: Mulligan suggested that injuries or sprains can cause a minor positional error in a joint, thereby causing limitations in physiological movement. Unique to this concept is mobilization of the spine while weight bearing and directing the mobilization parallel to the spinal facet planes. Although it includes various mobilization techniques, one of the most important techniques, motion co-mobilization, is the SNAG's technique, which includes the application of accessory passive gliding to the lumbar vertebra while the patient performs active movement simultaneously.
Study NCT05334394 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Therapy
Description: Exercise is recommended by physical therapists for most chronic low back pain patients.
Study NCT05849077 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sat75
Description: As per the current NRP guidelines, resuscitation will be initiated with 0.3 FiO2. FiO2 will be titrated every 30 seconds by 0.2-0.3 to achieve target SpO2 that approximates the 75th percentile SpO2 observed in healthy term newborns. Percentiles are roughly based on Dawson reference curves of healthy term infants after birth. Apart from the randomly assigned target SpO2, resuscitation will follow the current NRP guidelines. Following NICU admission, all care decisions, including ventilator management, will be at the discretion of the clinical team.
Study NCT05849077 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sat50
Description: As per the current NRP guidelines, resuscitation will be initiated with 0.3 FiO2. FiO2 will be titrated every 30 seconds by 0.1-0.2 to achieve target SpO2 that approximates the 50th percentile SpO2 observed in healthy term newborns. Percentiles are roughly based on Dawson reference curves of healthy term infants after birth. Apart from the randomly assigned target SpO2, resuscitation will follow the current NRP guidelines. Following NICU admission, all care decisions, including ventilator management, will be at the discretion of the clinical team.
Study NCT04827901 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: XEN1101
Description: two 10 mg capsules
Study NCT04827901 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo
Study NCT05652647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral [14C]PF-07081532
Description: A single oral dose of \[14C\]PF-07081532, will be administered as a liquid formulation in study period 1.
Study NCT05652647 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral PF-07081532 and IV [14C]PF-07081532
Description: In study period 2: a single, oral, unlabeled dose of PF-07081532 will be administered as a liquid formulation. Approximately 1 hours after the administration of the unlabeled oral dose, a single dose of \[14C\]PF-07081532 will be administered via intravenous infusion.
Study NCT04743791 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dupilumab
Description: Dupilumab is supplied as a sterile aqueous solution for SC injection at the concentration of 175 mg/mL in glass pre-filled syringe to deliver 200 mg in 1.14mL.
Study NCT05052580 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: COVID-19 Testing
Description: Participants who consent to participate in this study will be tested at days 1, 3, 5, and 7 following a known COVID-19 exposure on day 0. If the COVID-19 tests are negative, the participant will remain in the school environment. A positive COVID-19 test or the development of symptoms on any day after exposure would require isolation according to school, local and state guidelines.
Study NCT06336785 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane line of soft tissue fillers and Dysport neuromodulator
Description: Subjects will be treated with a range of hyaluronic acid-based soft tissue fillers (Restylane line) and Dysport neuromodulator
Study NCT04743791 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile placebo for dupilumab will be provided in identically matched glass pre-filled syringe to deliver 200 mg in 1.14mL, which will match dupilumab 200 mg (1.14mL).
Study NCT06365619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Two cycles of neoadjuvant ipilimumab prior to surgical resection.
Study NCT06365619 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: two cycles of neoadjuvant nivolumab prior to surgical resection.
Study NCT05465083 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lungpacer AeroPace Protect System
Description: AeroPace Catheter will be placed percutaneously into the left internal jugular vein or left subclavian vein and stimulating electrodes mapped for therapy.
Study NCT05797610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO7434656
Description: RO7434656 will be administered subcutaneously per schedule as specified.
Study NCT05797610 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be administered subcutaneously per schedule as specified.
Study NCT06347874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cryoablation
Description: an injection of 1ml of 1% lidocaine per rib and ultrasound guided cryoablation of the intercostal nerves
Study NCT06347874 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ESP Catheter
Description: an ultrasound guided erector spinae plane catheter with initial bolus of 30 mL of 0.25% bupivacaine followed by infusion of 0.2% ropivacaine at 10 mL per hour via programmed intermittent bolus.
Study NCT05488145 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Practice
Description: Receive standard of care
Study NCT05488145 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Based Intervention
Description: Receive application intervention
Study NCT05488145 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: PROMIS medication adherence questionnaire is a well-defined self-report measure of medication-taking habits used to objectively assess adherence to medication and therapy. At the end of the study period, we will perform data analysis.
Study NCT05488145 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Improvement in patient satisfaction will be measured by utilizing Consumer Assessment of Healthcare Providers and Systems (CAHPS) Cancer Care Survey scores. Surveys will be conducted among all participants at baseline and at 12 weeks, regardless of their use of the app, to better understand any barriers to using the app and which aspects of the app were most useful to patients.
Study NCT06081153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: See arm description.
Study NCT06081153 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: See arm description.
Study NCT06142773 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tidal Volume set on ventilator
Description: Mechanically ventilated patients who are undergoing MRI examinations under general anesthesia in isocapnic and isoxic conditions will have brain activity investigated under two different tidal volumes, 6 ml/kg and 12 ml/kg applied for 3-5 minutes.
Study NCT06142773 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tidal Volume set on ventilator
Description: Mechanically ventilated patients who are undergoing MRI examinations under general anesthesia in isocapnic and isoxic conditions will have brain activity investigated under two different tidal volumes, 6 ml/kg and 12 ml/kg applied for 3-5 minutes.
Study NCT04972942 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Daratumumab
Description: Total body irradiation (TBI)-based myeloablative allogeneic hematopoietic stem cell transplantation (HCT) using best available donor.~Daratumumab (DARA) treatment post-HCT Phase 1: 3 dose levels to determine safety (15 patients)~Dose expansion:~1. Induction: DARA IV weekly x 8 doses (Weeks 1-8)~2. Consolidation: DARA every 2 weeks x 8 doses (Weeks 9-24)~3. Maintenance: DARA every 4 weeks (Stop at Day +270)
Study NCT06239389 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thalidomide 100mg
Description: Thalidomide is available in capsulated form in the strength of 100 mg and 50 mg. It was given according to the weight of the patient. Due to somnolence, it was advised to give at night only.
Study NCT06239389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Description: Hydroxyurea is available in capsulated form under the brand of hydrea. Its available strength is 500 mg . Dosing depends upon weight of patient, that is 15mg/kg/day. so patients unable to take full capsule due to low weight, was advised to take hydroxyurea syrup.
Study NCT05446285 — intervention group
Intervention type: OTHER
Intervention: Clinical assessment
Description: All participants will be invited to attend their local research facility to undergo a physical and questionnaire assessment as well as an MRI. Assessments include: Expanded Disability Status Scale, 9-Hole Peg Test, MRI scan, Patient Reported Outcome Measures (MSIS-29, neuroQOL and PROMIS), Brief International Cognitive Assessment for MS)
Study NCT05021653 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: No intervention involved
Study NCT05278468 — intervention group
Intervention type: OTHER
Intervention: PCR test for covid-19
Description: real-time reverse transcription polymerase chain reaction results for severe acute respiratory syndrome coronavirus-19 (COVID-19) infection.
Study NCT06227650 — intervention group
Intervention type: DEVICE
Intervention: hybrid closed loop insulin delivery system
Description: Patients with secondary pancreatic diabetes equipped with a hybrid closed loop insulin delivery device
Study NCT06202859 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MIE
Description: Two sequences separated for 1 min of 6 cycles each of MI-E(Cough Assist E70, Respironics Philips.
Study NCT06202859 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MIE
Description: Two sequences separated for 1 min of 6 cycles each of MI-E(Cough Assist E70, Respironics Philips.
Study NCT05171907 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Teleobesity
Description: Teleintervention based on Dietary Guidelines for the Brazilian Population during 8 weeks; two subsequent assessments will also be made, in 24th and 48th weeks, to assess the maintenance of weight loss.
Study NCT05058989 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Advanced ultrasound measurements (Duplex ultrasound (DUS) and Vector flow imaging (VFI)
Description: PPG is a non-invasive method used to evaluates the severity venous reflux by measuring the venous refiling time (VRT).The principal of PPG works by using a small light source and a photoelectric cell attached to the skin in the medial supramalleolar area of the leg (the distal lower medial area of the leg).
Study NCT05058989 — intervention group
Intervention type: OTHER
Intervention: Clinical interventions and procedures
Description: First trimester (0-13 weeks):~* Consent~* Clinical data collection~* Blood samples (genomic+ hormonal)~* Duplex ultrasound~* Vector flow imaging (advanced ultrasound software)~* Truncated cone tool (measuring leg circumference using a tape measure)~* PPG~* AVVQ (Aberdeen varicose veins questionaire)~Second trimester (14-26 weeks):~* Clinical data collection~* Blood sample (hormonal only)~* DUS~* VFI~* Truncated cone tool~* PPG~* AVVQ~Third trimester (27-40 weeks):~Same as second trimester~Three months after giving birth:~Same as second trimester